Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development

被引：4

作者：

Yang, Wenzhan ^{[1
]}

Bhattachar, Shobha N. ^{[2
]}

Patel, Phenil J. ^{[3
]}

Landis, Margaret ^{[4
]}

Patel, Dipal ^{[5
]}

Reid, Darren L. ^{[6
]}

Romic, Marieta Duvnjak ^{[7
]}

机构：

[1] AstraZeneca, Adv Drug Delivery, Pharmaceut Sci, R&D, Boston, MA 02451 USA

[2] Eli Lilly & Co, Discovery Chem Res & Technol, Indianapolis, IN 46285 USA

[3] Eli Lilly & Co, Small Mol Design & Dev, Indianapolis, IN 46285 USA

[4] Pfizer Global Res & Dev, Mol Pharmaceut, Pharmaceut Sci, Cambridge, MA 02139 USA

[5] Bristol Myers Squibb Inc, Dept Metab & Pharmacokinet, Princeton, NJ 08543 USA

[6] Amgen Inc, Drug Prod Technol, Prepivotal Drug Prod & Cellular Sci, Cambridge, MA 02142 USA

[7] Novartis Pharma AG, Tech Res & Dev, CH-4002 Basel, Switzerland

来源：

DRUG DISCOVERY TODAY | 2021年 / 26卷 / 03期

关键词：

D O I：

10.1016/j.drudis.2020.12.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited to post-launch efforts improving therapeutic outcomes. Recently, they have gained renewed importance because the pharmaceutical industry is steadily shifting to a more integrated discovery-development approach. In discovery, modulating target engagement via drug-delivery technologies can enable crucial pharmacological studies for building well-defined criteria for molecular design. In development, earlier implementation of delivery technologies can enhance the value of drug products through reduced dosing frequency and improved tolerability and/or safety profile, thereby leading to better adherence and therapeutic effectiveness.

引用

页码：713 / 723

页数：11

共 50 条

[11] iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery
Zhang, Ru
Zhang, Li-hong
Xie, Xin
[J]. ACTA PHARMACOLOGICA SINICA, 2013, 34 (06) : 765 - 776
[12] Computational approaches in target identification and drug discovery
Katsila, Theodora
Spyroulias, Georgios A.
Patrinos, George P.
Matsoukas, Minos-Timotheos
[J]. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2016, 14 : 177 - 184
[13] Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery
Jung, Hye Jin
Kwon, Ho Jeong
[J]. ARCHIVES OF PHARMACAL RESEARCH, 2015, 38 (09) : 1627 - 1641
[14] Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery
Hye Jin Jung
Ho Jeong Kwon
[J]. Archives of Pharmacal Research, 2015, 38 : 1627 - 1641
[15] Cellular target engagement: a new paradigm in drug discovery
Babic, Ivan
Kesari, Santosh
Nurmemmedov, Elmar
[J]. FUTURE MEDICINAL CHEMISTRY, 2018, 10 (14) : 1641 - 1644
[16] Approaches to oral drug delivery for challenging molecules
Mustata, Gabriela
Dinh, Steven M.
[J]. CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2006, 23 (02): : 111 - 135
[17] Molecular Pharmacologic approaches to functional analysis of new biological target molecules for drug discovery
Baba, Akemichi
[J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2007, 127 (10): : 1643 - 1654
[18] Discovery solubility measurement and assessment of small molecules with drug development in mind
Barrett, Jaclyn A.
Yang, Wenzhan
Skolnik, Suzanne M.
Belliveau, Lisa M.
Patros, Kellyn M.
[J]. DRUG DISCOVERY TODAY, 2022, 27 (05) : 1315 - 1325
[19] Proteomic approaches in drug discovery and development
Soares, HD
Williams, SA
Snyder, PJ
Gao, F
Stiger, T
Rohlff, C
Herath, A
Sunderland, T
Putnam, K
White, WF
[J]. HUMAN BRAIN PROTEOME, 2004, 61 : 97 - +
[20] Introduction to the Theme "New Approaches for Studying Drug and Toxicant Action: Applications to Drug Discovery and Development"
Insel, Paul A.
Amara, Susan G.
Blaschke, Terrence F.
Meyer, Urs A.
[J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58, 2018, 58 : 33 - 36

← 1 2 3 4 5 →